Clinical trial NCT01762800
Conditions: Pulmonary Disease, Chronic Obstructive
Sponsor: GlaxoSmithKline
Start date: 2013-02-01; Completion date: 2015-09-01
Enrollment: 407 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011. This study is conducted in Japanese subjects with COPD and assess whether the GOLD 2011 strategy is effective in medical practice in Japan.

Detailed description:
PROTOCOL SUMMARY Rationale Both ADOAIR and tiotropium bromide ( hereinafter tiotropium）are now well established, effective treatments for COPD and are frequently co-prescribed (hereinafter TRIPLE therapy). The addition of ADOAIR to tiotropium improves lung function and quality of life and may further reduce exacerbations. GOLD 2011 thus recommends TRIPLE therapy as the second choice of COPD treatment strategy. However, the criteria for switching from each individual treatment to TRIPLE therapy are not clearly shown so far.

This study will be conducted in Japanese subjects with COPD and will assess whether the GOLD 2011 strategy is effective in medical practice in Japan.

Objective(s) The objective of the study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011.

Study Design Multicenter, randomized, double-dummy, 24-weeks, observational study Study Endpoints/Assessments Primary

* Proportion of patients who were able to remain on the randomized therapy Secondary
* Proportion of patients who switched to TRIPLE therapy
* Proportion of patients who controlled by TRIPLE therapy
* Proportion of patients controlled by randomized therapy plus TRIPLE therapy
* Time to switching to TRIPLE therapy
* Time to first exacerbation
* Proportion of diagnosed exacerbation confirmed by Daily Record Card
* Proportion of exacerbations detected by Daily Record Card not diagnosed
* CAT score change
* Change in FEV1
* Use of relief medication
* Proportion of patients who decreased treatment from TRIPLE therapy
* Proportion of patients who required additional treatment to TRIPLE therapy
* Proportion of patients who dropped out
* Patients' judgment of treatment efficacy
* Physician's judgment of treatment efficacy

Safety

* Adverse event reporting
* Exacerbations of COPD

Arms: arm 1: Randomised treatment at Visit 2 arm 2: Randomised treatment at Visit 2
Interventions: intervention 1: fluticasone propionate/salmeterol 50/250mcg intervention 2: fluticasone propionate/salmeterol placebo intervention 3: tiotropium bromide 18mcg intervention 4: tiotropium bromide placebo intervention 5: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
Intervention descriptions: intervention 1: Active, 50/250mcg, Twice daily (morning and evening) intervention 2: Placebo, Twice daily (morning and evening) intervention 3: Active, 18mcg, Once daily(morning) intervention 4: Placebo, Once daily(morning) intervention 5: Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.

Protocol documents: